Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   201 Trials   201 Trials   5390 News 


«12...678910111213141516...6970»
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  A Case Study of Successful Breast Cancer Treatment after Recovery from Drug-Induced Interstitial Lung Disease (Pubmed Central) -  May 27, 2023   
    In the second case, a patient on anti-HER2 therapy for recurrent disease developed DILD in response to docetaxel plus trastuzumab plus pertuzumab administered to treat T-DM1 after progressive disease. In this report, we describe a case of DILD that did not worsen and the patient had successful treatment outcome.
  • ||||||||||  Herceptin (trastuzumab) / Roche, SIBP-01 (trastuzumab biosimilar) / Sinopharm, Perjeta (pertuzumab) / Roche
    Journal, Combination therapy:  Efficacy and Safety of Trastuzumab Biosimilars in Combination with Pertuzumab (Pubmed Central) -  May 27, 2023   
    The incidence of adverse events was not significantly different between the reference biological product and biosimilars, and no increase was observed for any adverse events after switching to the biosimilars. The results of this study verify that a combination of trastuzumab biosimilars with pertuzumab is sufficiently effective and safe in clinical practice.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
    Review, Journal, Metastases:  History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer. (Pubmed Central) -  May 27, 2023   
    Recently, a novel anti-HER2 agent, trastuzumab deruxtecan, was introduced, and the development of HER2-positive gastric cancer agents has been moving to the next stage. This review summarizes the current HER2-targeted therapy for gastric or gastroesophageal cancer in chronological order and describes the promising future of HER2-targeted therapy.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
    Review, Journal:  Radiotherapy and targeted therapy for the management of breast cancer: A review (Pubmed Central) -  May 13, 2023   
    Moreover, there is a great heterogeneity between these studies regarding the dose and fractionation used in radiotherapy, the dosage of systemic treatments and the sequence of treatments used. Therefore, the combination of these new molecules with radiotherapy should be proposed sparingly, under close monitoring, pending the ongoing prospective studies cited in this review.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche
    Journal:  Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort. (Pubmed Central) -  May 9, 2023   
    Multivariate Cox regression analysis showed that better performance status (hormone receptor [HR]: 0.30, 95% CI: 0.13-0.71, P = .006), use of trastuzumab plus pertuzumab prior to T-DM1 (HR: 0.37, 95% CI: 0.18-0.76, P = .007) and use of statins with T-DM1 (HR: 0.29, 95% CI: 0.12-0.70, P = .006) were independent factors that prolong OS duration. Our study showed that T-DM1 is more effective at treating HER2-positive breast cancer in people who receive statins concurrently with T-DM1 than those who do not.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics. (Pubmed Central) -  May 7, 2023   
    Our study showed that T-DM1 is more effective at treating HER2-positive breast cancer in people who receive statins concurrently with T-DM1 than those who do not. Using these biologics simultaneously as biparatopic theranostic agents has additive benefits.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Trial completion date, Trial primary completion date:  HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (clinicaltrials.gov) -  May 6, 2023   
    P1,  N=31, Active, not recruiting, 
    Using these biologics simultaneously as biparatopic theranostic agents has additive benefits. Trial completion date: Aug 2024 --> Aug 2026 | Trial primary completion date: Aug 2023 --> Aug 2026
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Preclinical, Journal:  Generation of Rat Monoclonal Antibodies Against Human Epidermal Growth Factor Receptor 2. (Pubmed Central) -  May 3, 2023   
    In this study, we describe rat mAbs, which were generated against the ECD of human HER2. The human breast cancer cell line SK-BR-3 was subjected to immunofluorescence staining as it expresses HER2, and mAbs can detect both intact and endogenous HER2 within the cell line.
  • ||||||||||  Journal:  Targeting human EGFR 2 (HER2) in salivary gland carcinoma. (Pubmed Central) -  Apr 28, 2023   
    T-DM1 or T-Dxd can be considered upon disease progression on trastuzumab-combination therapies, although these antibody-drug conjugates can also be used upfront. Future research should investigate predictive biomarkers, the combination of HER2 and androgen blockade, and the application of novel therapies from breast cancer.
  • ||||||||||  Evolution of cancer treatment costs in the last 36 months in a self-funded health care in Brazil. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_6028;    
    In this study, the cost of cancer treatment has increased 40.5%, especially in the last period, which coincides with the expansion of the list of mandatory coverages and due to the resumption of procedures after COVID-19. Minimizing the financial impact of the new technologies, through responsible management focused on the patient and based on the best scientific evidence, is fundamental for maintaining the sustainability.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Real world evidence for continuing HER2-directed therapy for metastatic breast cancer. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_5839;    
    The majority of eligible patients do ultimately secure access despite prohibitive public funding policies. Receiving further HER2Rx was associated with a significant and clinically meaningful OS benefit of 28 months over those who go on to receive non-HER2 directed therapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_4766;    
    RNA-seq is emerging as an objective tool to evaluate key diagnostic and targetable events in multiple cancer types. The use of RNA-seq can also add value as an objective measurement to confirm critical IHC findings, potentially changing clinical care.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Shifting trends in the usage of trastuzumab with its biosimilar inception in India. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_4264;    
    Biosimilars are preferred option amongst oncologists in India because of affordability and accessibility. The availability of quality biosimilars has the potential to reduce health care expenditure, and an effective supply also increase patient
  • ||||||||||  ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_4263;    
    In our study, the new generation ADC significantly improved PFS and ORR compared with that for T-DM1 with manageable toxicity, so it can be considered an optimized subsequent treatment for HER2 positive advanced breast cancer after TKI failure. In addition, there was no significant difference in PFS and CBR between HP and the new generation ADC, thus HP dual-antibody regimen is also an optional treatment for patients who never used pertuzumab.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_4257;    
    A survival and prognostic stratification model was constructed based on the clinicopathological characteristics and treatment pattern of a large cohort of HER2-positive breast cancer patients with brain metastases, and the patients were divided into the low-risk group, intermediate-risk group and high-risk group. The optimal individualized treatment strategy was recommended according to different groups.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Characterization of patients with recurrent breast cancer submitted to neoadjuvant therapy in a Brazilian cancer center. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_4244;    
    Regarding neoadjuvant chemotherapy, 92% received anthracycline and taxane, 23% dose-dense, 17.4% received trastuzumab with or without pertuzumab, and 20% of ER-/HER2- received carboplatin...Ninety percent received adjuvant radiotherapy, 9.2% adjuvant capecitabine and 45% of HR+ adjuvant tamoxifen... Recurrence was associated with intrinsic factors, such as HG III, Ki67>20%, cT4, cN3/4 and molecular subtype, as well as RCB > II/III, treatment interruption and choice of adjuvant hormonal therapy, pointing out possible risk factors in our population.